Updates on HER2-Directed ADCs Across Solid Tumors - Episode 10
The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
Vijayakrishna Gadi, MD, University of Illinois College of Medicine, Susana Campos, MD, MPH, Matthew D. Galsky, MD, Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA, Aparna R. Parikh, MD Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.
Video content above is prompted by the following:
- A discussion surrounding earlier treatment lines involving HER2-targeted ADCs.